long intergenic non-protein coding RNA 1750Genealiases: []
Q-omics provides the consensus-scored LINC01750 profile across patient tissues and cancer cell-line models. LINC01750 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01750 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, LINC01750 RNA expression shows 15,642 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, KICH, and LSCC as cancer lineages where LINC01750 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01750 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01750 survival associations across molecular data types. LINC01750 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01750 RNA expression–survival associations across cancer types. High LINC01750 expression shows unfavorable associations in KIRC, but favorable associations in LUAD, MESO, KIRP, SARC and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01750 RNA expression.
This table summarizes LINC01750 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01750. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01750 shows lower tumor expression in KICH, THCA, UCEC, BLCA, LUAD and BRCA. The KICH box plot shows higher LINC01750 RNA expression in normal versus tumor tissue (log2 FC = −0.541, t-test p < 0.001).
This table shows molecular features associated with LINC01750 in patient tissues and cancer cell lines. In patient samples, LINC01750 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
